Discover
Humira (adalimumab) / Eisai, AbbVieStudy to Evaluate the Safety and Efficacy of Two Drug Regimens in Subjects With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - Nov 22, 2019 - P3; N=952; Completed; Sponsor: AbbVie; Active, not recruiting --> CompletedXifaxan (rifaximin) / Alfa Wassermann, Bausch Health, NorgineXifaxan clinical trial estimate: Interim data from P2 trial (NCT03515044) for overt hepatic encephalopathy in Q4 2019 (Cowen & Co) - Nov 18, 2019 - A subscription to Thomson ONE is required to gain full access to report 68320235; Page no: 2; REPORT TITLE: "Bausch Health Companies Inc- Model update: Thesis unchanged – Reiterate (1)”; AUTHOR: Cacciatore, Ken, et al; DATE: 11/11/2019PTG-200 / Protagonist Therapeutics, J&JPTG-200: Data from P2 trial for Crohn’s disease in H1 2021 (Stifel 2019 Healthcare Conference, Protagonist Therapeutics) - Nov 21, 2019 [Screenshot]Xeljanz (tofacitinib) / PfizerXeljanz: “The Committee discussed the issues identified in this application, mainly concerning the clinical efficacy data and the feasibility of a registry analyses [extension application to introduce a new pharmaceutical form (prolonged-release tablet) associated with a new strength (11 mg)]”. (EMEA) - Nov 19, 2019 - CHMP Final Minutes for the meeting on 16-19 September 2019: “The Committee adopted the CHMP recommendation and scientific discussion together with a 3rd list of outstanding issues and a specific timetable.”etrasimod (APD334) / ArenaCULTIVATE: A Study Evaluating the Efficacy and Safety of Etrasimod in the Treatment of Patients With Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Nov 21, 2019 - P2b; N=225; Not yet recruiting; Sponsor: Arena Pharmaceuticalsfilgotinib (GLPG0634) / GileadFilgotinib pricing projection: $50,00/year (SunTrust) - Nov 22, 2019 - A subscription to Thomson ONE is required to gain full access to report 68321433; Page no: 59; REPORT TITLE: "Gilead Sciences Inc.-Initiating coverage - Initiating at Hold and $70 PT; HIV deep-dive on patent cliffs & PrEP”; AUTHOR: Research Department; DATE: 11/11/2019Remicade (infliximab) / Mitsubishi Tanabe, J&JDoctor urges Alberta not to switch coverage to cheaper meds for patients with IBD (Yahoo News) - Nov 21, 2019 - "Alberta is looking to switch to covering a cheaper alternative medication for patients with inflammatory bowel disease (IBD) — a move an expert says could harm some patients' health...The minister's office said in the past decade, the province's spending on biologics has increased from around $20 million per year to more than $200 million...But the maker of Remicade, one of the biologics for Crohn's patients that would be impacted, said it has reached out to the government to offer its product at a cost comparable to biosimilars."Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, NorginePatent delisted for Xifaxan from Orange Book (Orange Book) - Nov 20, 2019 - Patent no. 10314828 [Screenshot]
